CPT1A and cancer: Dihydroartemisinin treatment significantly reduces the expressions of c-Myc and its downstream targets ACC, FASN, CPT-1, and MCAD, which changes the lipid metabolism and the metabolic phenotypes in CRC, reduces energy production, cell proliferation, and induces cancer-cell death.